Literature DB >> 2516762

[Autoantibodies directed against membrane phospholipid in serum in patients with malignant tumors].

S Faiderbe1, J L Chagnaud, J Wafflart, M Geffard.   

Abstract

Modifications of membrane lipids in the levels of fatty acids and phospholipids are associated with malignant tumors. In order to evaluate if these changes are recognized by the immune system, we have attempted to assay the possible presence of autoantibodies directed against the following lipids: phosphatidylinositol (PI), phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, gangliosides, galactocerebrosides, sphingomyelin, sphingosin, and cardiolipin, in the sera of patients with malignant tumors (n = 324) and from controls [healthy subjects (n = 20) and patients suffering of other diseases (n = 60)]. Using an adaptated immunoenzymatic assay (ELISA method), a highly significant difference (p less than 0.001) was found between the mean absorbances read on the cancer and control group for only one lipid, the PI. Whatsmore, these auto anti-PI were found in all sera (diluted 15,000 times) of patients with malignant tumors, whatever type, grade, or organ localization defined. These data indicated that the immune system recognized the PI antigenic modifications which appear to be linked to the cell transformation. This PI-immunological binding may have a predictive value as we have recently noticed in animals bearing chemically-induced malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2516762

Source DB:  PubMed          Journal:  C R Acad Sci III        ISSN: 0764-4469


  2 in total

Review 1.  Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential.

Authors:  M A Altinoz; S Guloksuz; I Elmaci
Journal:  Clin Transl Oncol       Date:  2017-01-16       Impact factor: 3.405

Review 2.  Usage of cancer associated autoantibodies in the detection of disease.

Authors:  Steven P Dudas; Madhumita Chatterjee; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.